SG121035A1 - Alpha crystalline form of strontium ranelate, a process for its preparation, and pharmaceutical compositions containing it - Google Patents

Alpha crystalline form of strontium ranelate, a process for its preparation, and pharmaceutical compositions containing it

Info

Publication number
SG121035A1
SG121035A1 SG200503938A SG200503938A SG121035A1 SG 121035 A1 SG121035 A1 SG 121035A1 SG 200503938 A SG200503938 A SG 200503938A SG 200503938 A SG200503938 A SG 200503938A SG 121035 A1 SG121035 A1 SG 121035A1
Authority
SG
Singapore
Prior art keywords
preparation
pharmaceutical compositions
crystalline form
compositions containing
strontium ranelate
Prior art date
Application number
SG200503938A
Other languages
English (en)
Inventor
Stephane Horvath
Isabelle Demuynck
Gerard Damien
Original Assignee
Servier Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34942420&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SG121035(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Servier Lab filed Critical Servier Lab
Publication of SG121035A1 publication Critical patent/SG121035A1/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D333/00Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/38Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Rheumatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)
  • Fodder In General (AREA)
SG200503938A 2004-09-30 2005-06-17 Alpha crystalline form of strontium ranelate, a process for its preparation, and pharmaceutical compositions containing it SG121035A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0410335A FR2875807B1 (fr) 2004-09-30 2004-09-30 Forme cristalline alpha du ranelate de strontium, son procede de preparation, et les compositions pharmaceutiques qui la contiennent

Publications (1)

Publication Number Publication Date
SG121035A1 true SG121035A1 (en) 2006-04-26

Family

ID=34942420

Family Applications (1)

Application Number Title Priority Date Filing Date
SG200503938A SG121035A1 (en) 2004-09-30 2005-06-17 Alpha crystalline form of strontium ranelate, a process for its preparation, and pharmaceutical compositions containing it

Country Status (42)

Country Link
US (2) US7459568B2 (pt)
EP (2) EP1642897B9 (pt)
JP (2) JP2006104184A (pt)
KR (1) KR100816590B1 (pt)
CN (1) CN100391956C (pt)
AP (1) AP1930A (pt)
AR (1) AR049395A1 (pt)
AT (1) ATE411308T1 (pt)
AU (1) AU2005202718B2 (pt)
BR (1) BRPI0502228A (pt)
CA (1) CA2508824C (pt)
CO (1) CO5710195A1 (pt)
CR (1) CR7876A (pt)
CY (1) CY1108797T1 (pt)
DE (1) DE602005010359D1 (pt)
DK (1) DK1642897T3 (pt)
EA (1) EA008474B1 (pt)
EC (1) ECSP055859A (pt)
ES (1) ES2314593T3 (pt)
FR (1) FR2875807B1 (pt)
GE (1) GEP20074106B (pt)
GT (1) GT200500130A (pt)
HK (1) HK1086260A1 (pt)
HR (1) HRP20080652T3 (pt)
IL (1) IL169237A (pt)
MA (1) MA27815A1 (pt)
MX (1) MXPA05006407A (pt)
NO (1) NO333948B1 (pt)
NZ (1) NZ540802A (pt)
OA (1) OA13013A (pt)
PA (1) PA8638201A1 (pt)
PE (1) PE20060364A1 (pt)
PL (1) PL1642897T3 (pt)
PT (1) PT1642897E (pt)
RS (1) RS51110B (pt)
SA (1) SA05260168B1 (pt)
SG (1) SG121035A1 (pt)
SI (1) SI1642897T1 (pt)
TW (1) TWI367881B (pt)
UA (1) UA80008C2 (pt)
WO (1) WO2006035122A1 (pt)
ZA (1) ZA200504937B (pt)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2875807B1 (fr) * 2004-09-30 2006-11-17 Servier Lab Forme cristalline alpha du ranelate de strontium, son procede de preparation, et les compositions pharmaceutiques qui la contiennent
US20070292529A1 (en) * 2006-06-19 2007-12-20 Tabbiner Philip S Strontium compositions and methods of treating osteoporotic conditions
US20070292535A1 (en) * 2006-06-19 2007-12-20 Tabbiner Philip S Strontium compositions and methods of treating arthritic and or osteoporitic conditions
CN101206208B (zh) * 2006-12-19 2011-08-10 北京德众万全药物技术开发有限公司 一种用hplc法分析雷尼酸锶原料及其制剂的方法
KR20110066197A (ko) * 2008-09-29 2011-06-16 라티오팜 게엠베하 스트론튬 라넬레이트의 무수물 및 수화물 형태
IT1398542B1 (it) 2010-03-05 2013-03-01 Chemelectiva S R L Processo per la preparazione di un polimorfo
CN102241663B (zh) * 2010-05-10 2013-02-13 山东方明药业集团股份有限公司 一种雷奈酸锶八水合物的制备方法
WO2012143932A1 (en) * 2011-04-21 2012-10-26 Shilpa Medicare Limited Crystalline strontium ranelate form-s
CZ2011320A3 (cs) 2011-05-30 2012-12-12 Zentiva, K.S. Stabilní krystalická forma X stroncium ranelátu
EP2530068A1 (en) 2011-05-31 2012-12-05 Lacer, S.A. New strontium salts, synthesis and use thereof in the treatment of osteoporosis
WO2013013003A1 (en) 2011-07-21 2013-01-24 Emory University Methods for treating inflamatory conditions and states, and cancers by antagonizing nf-kb activation
CN102503931A (zh) * 2011-09-20 2012-06-20 浙江华海药业股份有限公司 一种雷尼酸锶晶形h的制备方法
WO2013113319A1 (en) * 2012-01-31 2013-08-08 Pharmathen S.A. Process for the preparation of strontium ranelate, intermediate or hydrates thereof
EP2641905A1 (en) 2012-03-23 2013-09-25 Urquima S.A. Solid forms of strontium ranelate and processes for their preparation
US8569514B1 (en) 2012-05-17 2013-10-29 Divi's Laboratories, Ltd. Process for the preparation of strontium ranelate

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2651497B1 (fr) * 1989-09-01 1991-10-25 Adir Nouveaux sels de metaux bivalents de l'acide n, n-di (carboxymethyl)amino-2 cyano-3 carboxymethyl-4 carboxy-5 thiophene, leur procede de preparation et les compositions pharmaceutiques les renfermant.
PL181304B1 (pl) 1994-07-22 2001-07-31 Lilly Co Eli Preparat farmaceutyczny do hamowania zmniejszania masy kosci PL PL PL PL PL PL PL PL PL PL
FR2749759B1 (fr) * 1996-06-17 1999-11-26 Adir Utilisation de sels de strontium pour l'obtention de compositions pharmaceutiques destinees au traitement de l'arthrose
DE19642451A1 (de) 1996-10-15 1998-04-16 Merck Patent Gmbh Aminothiophencarbonsäureamide
DE60215213T3 (de) * 2001-10-03 2010-07-01 Teva Pharmaceutical Industries Ltd. Herstellung von levofloxacin-hemihydrat
CA2471144C (en) * 2002-01-09 2011-06-07 Emisphere Technologies, Inc. Polymorphs of sodium 4-[(4-chloro-2-hydroxybenzoyl)amino]butanoate
AU2003258109A1 (en) * 2002-08-06 2004-02-23 Teva Pharmaceutical Industries Ltd. Novel crystalline forms of gatifloxacin
FR2844795B1 (fr) * 2002-09-24 2004-10-22 Servier Lab Nouveau procede de synthese industriel du ranelate de strontium et de ses hydrates
FR2844796A1 (fr) * 2002-09-24 2004-03-26 Servier Lab Nouveau procede de synthese industrielle du diester methylique de l'acide 5-amino-3-carboxymethyl-4-cyano-2- thiophenecarboxylique, et application a la synthese des sels bivalents de l'acide ranelique et de leurs hydrates
FR2844797B1 (fr) * 2002-09-24 2004-10-22 Servier Lab Nouveau procede de synthese industriel des tetraesters de l'acide 5-[bis (carboxymethyl)]-3-carboxymethyl-4-cyano-2- thiophenecarboxylique, et application a la synthese des sels bivalents de l'acide ranelique et de leurs hydrates
FR2875807B1 (fr) * 2004-09-30 2006-11-17 Servier Lab Forme cristalline alpha du ranelate de strontium, son procede de preparation, et les compositions pharmaceutiques qui la contiennent

Also Published As

Publication number Publication date
PL1642897T3 (pl) 2009-04-30
TWI367881B (en) 2012-07-11
EP1944302A1 (fr) 2008-07-16
EP1642897B1 (fr) 2008-10-15
CN1754878A (zh) 2006-04-05
PA8638201A1 (es) 2006-05-16
SI1642897T1 (sl) 2009-02-28
NZ540802A (en) 2006-11-30
IL169237A (en) 2010-12-30
NO20052998L (no) 2006-03-31
ECSP055859A (es) 2006-09-18
NO333948B1 (no) 2013-10-28
UA80008C2 (uk) 2007-08-10
CO5710195A1 (es) 2006-12-29
HRP20080652T3 (en) 2009-01-31
CA2508824C (fr) 2009-03-24
JP2006104184A (ja) 2006-04-20
NO20052998D0 (no) 2005-06-17
AP1930A (en) 2008-12-15
MXPA05006407A (es) 2006-04-05
EA008474B1 (ru) 2007-06-29
ATE411308T1 (de) 2008-10-15
CR7876A (es) 2007-12-10
SA05260168B1 (ar) 2009-02-25
DK1642897T3 (da) 2009-01-26
RS51110B (sr) 2010-10-31
AR049395A1 (es) 2006-07-26
MA27815A1 (fr) 2006-04-03
GT200500130A (es) 2005-12-20
US20060069271A1 (en) 2006-03-30
BRPI0502228A (pt) 2006-05-09
GEP20074106B (en) 2007-05-10
KR20060049966A (ko) 2006-05-19
ES2314593T3 (es) 2009-03-16
KR100816590B1 (ko) 2008-03-24
FR2875807B1 (fr) 2006-11-17
PT1642897E (pt) 2008-11-27
US7459568B2 (en) 2008-12-02
DE602005010359D1 (de) 2008-11-27
AU2005202718A1 (en) 2006-04-13
CY1108797T1 (el) 2014-04-09
CN100391956C (zh) 2008-06-04
FR2875807A1 (fr) 2006-03-31
PE20060364A1 (es) 2006-06-17
EP1642897B9 (fr) 2009-08-12
HK1086260A1 (en) 2006-09-15
ZA200504937B (en) 2006-04-26
US20080312314A1 (en) 2008-12-18
AP2005003323A0 (en) 2005-06-30
AU2005202718B2 (en) 2010-09-16
EA200500842A1 (ru) 2006-04-28
EP1642897A1 (fr) 2006-04-05
CA2508824A1 (fr) 2006-03-30
US7745482B2 (en) 2010-06-29
TW200610758A (en) 2006-04-01
OA13013A (fr) 2006-11-10
JP2010132669A (ja) 2010-06-17
WO2006035122A1 (fr) 2006-04-06

Similar Documents

Publication Publication Date Title
TWI367881B (en) Alpha crystalline form of strontium ranelate, a process for its preparation, and pharmaceutical compositions containing it
HK1098129A1 (en) New crystalline form iv of agomelatine, a process for its preparation and pharmaceutical compositions containing it
HK1098128A1 (en) New crystalline form v of agomelatine, a process for its preparation and pharmaceutical compositions containing it
SG130112A1 (en) New crystalline form iii of agomelatine, a process for its preparation and pharmaceutical compositions containing it
IL173959A0 (en) ?? crystalline form of ivabradine hydrochloride, a process for its preparation and pharmaceutical compositions containing it
SG131857A1 (en) δD-CRYSTALLINE FORM OF IV ABRADINE HYDROCHLORIDE, A PROCESS FOR ITS PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING IT
IL178544A (en) Crystalline form - δ of ivabradine hydrochloride, process for preparation and pharmaceutical preparations containing it
TWI315306B (en) Bd-crystalline form of ivabradine hydrochloride, a process for its preparation and pharmaceutical compositions containing it
ME02750B (me) Kristalni oblik gama - d iv abradin hlorhidrata, postupak njegove izrade i farmaceutske smeše koje ga sadrže
HK1096387A1 (en) ß-CRYSTALLINE FORM OF IVABRADINE HYDROCHLORIDE, A PROCESS FOR ITS PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING IT
IL179530A0 (en) Novel compounds, pharmaceutical compositions containing same and methods of use for same
SG110170A1 (en) New benzoindoline compounds, a process for their preparation and pharmaceutical compositions containing them
IL178620A0 (en) Crystalline 2-amino-3-cyanoquinoline derivatives, process of their preparation and pharmaceutical compositions containing them